Relmada Therapeutics Inc (RLMD)

04:35 AM

Relmada (NASDAQ: RLMD) raises $100M, adds NDV-01 and sepranolone - stocktitan.net

04:35 AM

02:22 AM

Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget

02:22 AM

12:49 PM

Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - Zacks Investment Research

12:49 PM

Apr 04, 2026

RLMD SEC FilingsRelmada Therapeutics Inc 10-K, 10-Q, 8-K Forms - stocktitan.net

Apr 04, 2026

Apr 04, 2026

RLMD PE Ratio & Valuation, Is RLMD Overvalued - intellectia.ai

Apr 04, 2026

Apr 03, 2026

Relmada Therapeutics (NASDAQ: RLMD) registers 33.7M shares for resale from $160M placement - stocktitan.net

Apr 03, 2026

Apr 02, 2026

Relmada Therapeutics Inc. (US75955J4022.SG) analyst ratings, estimates and forecasts - Yahoo Finance UK

Apr 02, 2026

Mar 31, 2026

RLMD Stock Soars Pre-Market: Phase 2 Bladder Cancer Trial Data Impresses Investors - MSN

Mar 31, 2026

Mar 30, 2026

Relmada Therapeutics (RLMD) price target increased by 59.26% to 14.62 - MSN

Mar 30, 2026

Mar 30, 2026

Relmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And See (NASDAQ:RLMD) - Seeking Alpha

Mar 30, 2026

Mar 30, 2026

With 20-plus years in drug development, Raj Pruthi joins PreveCeutical - stocktitan.net

Mar 30, 2026

Mar 29, 2026

Relmada wins bullish view at Piper Sandler on cancer therapy - MSN

Mar 29, 2026

Mar 28, 2026

Here’s what makes Mizuho bullish on Relmada Therapeutics Inc (RLMD) stock - msn.com

Mar 28, 2026

Mar 28, 2026

Wall Street analysts predict a 92.19% upside in Relmada Therapeutics (RLMD): Here's what you should know - MSN

Mar 28, 2026

Mar 27, 2026

Guidance Update: How do insiders feel about Relmada Therapeutics IncQuarterly Market Summary & AI Powered Buy/Sell Recommendations - baoquankhu1.vn

Mar 27, 2026

Mar 26, 2026

Wall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should Know - sharewise.com

Mar 26, 2026

Mar 26, 2026

Wall Street experts anticipate a potential 92.19% increase for Relmada Therapeutics (RLMD): Key Information You Need to Know - Bitget

Mar 26, 2026

Mar 26, 2026

Portfolio Update: Should I invest in Relmada Therapeutics Inc before earningsBuy Signal & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn

Mar 26, 2026

Mar 25, 2026

Relmada (RLMD) Q4 2025 Earnings Call Transcript - AOL.com

Mar 25, 2026

Mar 25, 2026

RLMD stock surges 42% in a week: Here's what you should know - MSN

Mar 25, 2026

Mar 25, 2026

how Fair Value analysis spotted Relmada’s 65% gain in 2024 By Investing.com - Investing.com Canada

Mar 25, 2026

Mar 25, 2026

how Fair Value analysis spotted Relmada’s 65% gain in 2024 - Investing.com

Mar 25, 2026

Mar 25, 2026

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Large Increase in Short Interest - MarketBeat

Mar 25, 2026

Mar 25, 2026

Piper Sandler initiates coverage of Relmada Therapeutics (RLMD) with overweight recommendation - MSN

Mar 25, 2026

Mar 25, 2026

Here’s What Makes Mizuho Bullish on Relmada Therapeutics Inc (RLMD) Stock - Insider Monkey

Mar 25, 2026

Mar 24, 2026

Relmada Therapeutics (RLMD) Gains on Positive Analyst Coverage - GuruFocus

Mar 24, 2026

Mar 24, 2026

Relmada stock wins bullish view at Piper Sandler (RLMD:NASDAQ) - Seeking Alpha

Mar 24, 2026

Mar 24, 2026

Piper Sandler Initiates Relmada Therapeutics(RLMD.US) With Buy Rating, Announces Target Price $12 - Moomoo

Mar 24, 2026

Mar 24, 2026

Relmada Therapeutics (NASDAQ:RLMD) Earns Overweight Rating from Analysts at Piper Sandler - MarketBeat

Mar 24, 2026

Mar 24, 2026

Piper Sandler Initiates Coverage on RLMD with Overweight Rating - GuruFocus

Mar 24, 2026

Mar 24, 2026

Relmada Therapeutics stock initiated at Overweight by Piper Sandler - Investing.com

Mar 24, 2026

Mar 22, 2026

Short Squeeze: Is Relmada Therapeutics Inc a speculative investment2026 Stock Rankings & Growth Focused Entry Reports - baoquankhu1.vn

Mar 22, 2026

Mar 21, 2026

Relmada Therapeutics Reports Strong 2025 Results, $160M Financing, and Advances NDV-01 Bladder Cancer Program to Phase 3 - Minichart

Mar 21, 2026

Mar 20, 2026

Relmada Therapeutics Charts Aggressive Path After Earnings Call - TipRanks

Mar 20, 2026

Mar 20, 2026

Relmada Highlights NDV-01 Data, Funding in 2025 Results - TipRanks

Mar 20, 2026

Mar 20, 2026

Relmada (NASDAQ: RLMD) narrows 2025 loss, funds NDV-01 Phase 3 push - Stock Titan

Mar 20, 2026

Mar 20, 2026

Relmada Therapeutics price target raised to $19 from $10 at Mizuho - TipRanks

Mar 20, 2026

Mar 20, 2026

RLMD: Mizuho Analyst Raises Price Target to $19, Maintains Outpe - GuruFocus

Mar 20, 2026

Mar 20, 2026

VR Adviser Adds Over 1 Million Savara Shares - AOL.com

Mar 20, 2026

Mar 20, 2026

Relmada Therapeutics (NASDAQ:RLMD) Price Target Raised to $19.00 - MarketBeat

Mar 20, 2026

Mar 20, 2026

Mizuho raises Relmada Therapeutics stock price target on trial data By Investing.com - Investing.com Australia

Mar 20, 2026

Mar 20, 2026

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2025 Earnings Call Transcript - Insider Monkey

Mar 20, 2026

Mar 20, 2026

Mizuho raises Relmada Therapeutics stock price target on trial data - Investing.com

Mar 20, 2026

Mar 20, 2026

Here's Why Ovid Therapeutics Stock Popped Higher Today - AOL.com

Mar 20, 2026

Mar 20, 2026

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Mar 20, 2026

Mar 20, 2026

Relmada Therapeutics Inc (RLMD) PT Raised to $19 at Mizuho - StreetInsider

Mar 20, 2026